Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria
by
Share this page:
by
Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria
We use RNA interference, or RNAi, to create medicines that silence the genes that cause or contribute to disease. Our goal is to provide life-changing therapies to people living with rare and common diseases.